A carregar...
Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy
Background and Objective: Ibrutinib has recently been approved in Europe for Waldenström Macroglobulinemia (WM) in symptomatic patients who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemo-immunotherapy. The aim of the study is to estimate the in...
Na minha lista:
| Publicado no: | J Mark Access Health Policy |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Routledge
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5700492/ https://ncbi.nlm.nih.gov/pubmed/29201288 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/20016689.2017.1393308 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|